Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT01555827
NA

Retinal Neurodegenerative Signs in Alzheimer's Diseases

Sponsor: University Hospital, Bordeaux

View on ClinicalTrials.gov

Summary

A few studies suggest that patients suffering from neurodegenerative diseases (such a multiple sclerosis or Alzheimer's disease (AD)) show decreased thickness of the retinal nerve fiber layer (RNFL), indicating axonal degeneration. High-definition spectral domain optical coherence tomography (SD-OCT), performed without radiation in a few seconds per eye, offers a precise and standardized estimation of this parameter, which could constitute a biomarker for cerebral axonal degeneration. These RNFL deficits might even be the earliest sign of AD, prior to damage of the hippocampal region that impacts memory. Besides, some associations of AD with some degenerative diseases of the eye (glaucoma, microvascular abnormalities, age-related macular degeneration (AMD)) have also been reported. It therefore seems interesting to determine whether RNFL thickness, and other ocular parameters, may give some indications for a better detection of AD and cognitive decline in the elderly.

Key Details

Gender

All

Age Range

50 Years - Any

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2012-03-12

Completion Date

2014-06-07

Last Updated

2026-05-14

Healthy Volunteers

Yes

Interventions

OTHER

Ophthalmological examination & Questionnaire

The following examinations will be performed, after pupil dilation: * Examination with SD-OCT (macular scans, macular volume, peri-papillary scan, retinal autofluorescence, infer-red and red-free imaging) * Colour photographs of the retinal, centered on the macula and on the optic nerve (digital non mydriatic retinal camera) * Wide-field colour and autofluorescence imaging (Optomap) * Measure of intra-ocular pressure (pneumotonometer) The following informations will be collected through a standardized questionnaire, administered face-to-face during the inclusion visit, or at the moment of the verification of eligibility criteria: * Age, gender * educational level * smoking * cardiovascular diseases, current medications * scores at neuropsychological tests

Locations (1)

CHU Bordeaux - hôpital Pellegrin

Bordeaux, France